Pharmaceutical The market for neuroendocrine tumors (NETs) – a rare type of tumor where cancerous growth can begin in any cell within the hormone or nervous system – is expected to see a very slow 0.9% compound annual growth rate (CAGR) over the next decade in the world’s eight major markets (8MM; The USA, France, Germany, Italy, Spain, the UK, Japan and China) due to substantial generic erosion and low levels of innovation. 29 September 2021